Prothena

Yahoo Finance • 9 hours ago

Prothena authorizes up to $100 million share repurchase plan

* Prothena Corporation (PRTA [https://seekingalpha.com/symbol/PRTA]) on Friday said that its board had authorized a share repurchase plan of up to $100 million of the company’s outstanding ordinary shares. * The biotechnology company s... Full story

Yahoo Finance • 9 hours ago

Prothena Announces up to $100 Million Share Repurchase Plan

DUBLIN, February 27, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announce... Full story

Yahoo Finance • 8 days ago

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full... Full story

Yahoo Finance • 4 months ago

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate... Full story

Yahoo Finance • 4 months ago

Prothena Corporation plc (PRTA): A Bull Case Theory

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 High-Potential Small-Caps With Market Cap Under $1B. We came across a bullish thesi... Full story

Yahoo Finance • 5 months ago

Bristol Myers Alzheimer's Drug Earns FDA Fast Track

This article first appeared on GuruFocus. Bristol Myers Squibb (NYSE:BMY) just got a boost in its Alzheimer's program after the FDA granted Fast Track designation to its experimental drug BMS-986446, now in phase 2 testing for patients in... Full story

Yahoo Finance • 5 months ago

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment... Full story

Yahoo Finance • 7 months ago

Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes

Prothena Corporation plc (NASDAQ:PRTA), a biotechnology company focused on developing novel therapies for neurodegenerative and rare peripheral amyloid diseases, has experienced significant shifts in its pipeline and market outlook. With a... Full story

Yahoo Finance • 7 months ago

Novo Nordisk boosts Prothena on plans for amyloidosis therapy

[New Nordisk] hapabapa/iStock Editorial via Getty Images * Prothena (NASDAQ:PRTA [https://seekingalpha.com/symbol/PRTA]) shares spiked on Wednesday after Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) during its Q2 earnings ca... Full story

Yahoo Finance • 7 months ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program... Full story

Yahoo Finance • 7 months ago

Life360 Reaches Analyst Target Price

In recent trading, shares of Life360 Inc (Symbol: LIF) have crossed above the average analyst 12-month target price of $76.12, changing hands for $76.93/share. When a stock reaches the target an analyst has set, the analyst logically has... Full story

Yahoo Finance • 7 months ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and investing activities was $99.8 million for the first six months of 2025; quarter-end cash and restricted cash po... Full story

Yahoo Finance • 8 months ago

Prothena announces 63% workforce reduction following birtamimab halt

Prothena Corporation plc (NASDAQ:PRTA) announced a significant workforce reduction of approximately 63% to substantially reduce operating costs following its decision to discontinue development of birtamimab, according to an SEC filing on... Full story

Yahoo Finance • 8 months ago

Prothena to lay off 63% of workforce, revises full year guidance

* Prothena (NASDAQ:PRTA [https://seekingalpha.com/symbol/PRTA]) has initiated an around 63% reduction in its workforce to substantially reduce its operating costs to those necessary to support its remaining wholly owned programs, its obl... Full story

Yahoo Finance • 8 months ago

Prothena to cut workforce by 63% amid strategic review

DUBLIN - Prothena Corporation plc (NASDAQ:PRTA), currently trading at $5.75 and down over 70% in the past year, announced Wednesday it has initiated an approximate 63% reduction in its workforce to substantially reduce operating costs whil... Full story

Yahoo Finance • 8 months ago

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena Corporation plc (NASDAQ:PRTA), has announced plans to initiate Phase 3 development of prasinezumab for early-stage Parkin... Full story

Yahoo Finance • 8 months ago

Prothena jumps as partner Roche to advance Parkinson's drug into late-stage studies

[Parkinsons Disease Torn Paper Concept] IvelinRadkov * Shares of Prothena Corporation (NASDAQ:PRTA [https://seekingalpha.com/symbol/PRTA]) added ~11% in the premarket on Monday after the biotech said its partner Roche (OTCQX:RHHBF [http... Full story

Yahoo Finance • 8 months ago

Roche to advance Parkinson's disease antibody to Phase III trials

DUBLIN - Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson’s disease, Prothena Corporation plc (NASDAQ:PRTA) announced Monday. The announcement comes as... Full story

Yahoo Finance • 9 months ago

Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results

On May 27,  Jefferies downgraded Prothena Corporation plc (NASDAQ:PRTA) to Hold from Buy and slashed the price target to $6 from $32. The considerable price target reduction followed the company's announcement regarding the discontinuatio... Full story

Yahoo Finance • last year

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ: PRTA) breached their fiduciary duties to shareho... Full story